



PRESS RELEASE

EXCiPACT GMP/GDP CERTIFICATION SCHEME FREE-TO-ATTEND SEMINAR, FRANKFURT, GERMANY, 20 MARCH 2019

Brussels, 29 January, 2019

EXCiPACT asbl is pleased to announce details of their free-to-attend seminar to be held in Frankfurt at DQS offices on Wednesday, 20th March, 2019 with the following programme¹:

09.45h	Registration/Coffee
10.15h	Welcome & Introduction – <i>DQS Representative</i>
10.30h	Introduction to EXCiPACT organisation and Scheme - <i>EXCiPACT Representatives</i> Understanding of EU regulations for Pharma excipients
11.30h	Coffee break
11.45h	Outline of the EXCiPACT Certification Process - <i>DQS Representative</i>
12.15h	Lunch Break
13.15h	Case study on EXCiPACT Certification – Certified company representative
14.15h	Pharma Company User Experience
15.15h	Q & A session – all speakers
15.30h	Close meeting

This seminar has been organised in an easy-to-access location to meet the needs of those in the European pharmaceutical excipient supplier and user community who wish to learn more about the EXCiPACT GMP/GDP Certification Scheme in an educational environment with ample time for questions and networking with informed speakers and other delegates. Typical participants would be QA Directors & Managers in excipient supplier companies and Heads of Supplier Qualification, Procurement Heads and Specialists in pharma companies.

To book your free place, contact the EXCiPACT Secretariat on info@excipact.org. Final details will be sent to all registrants by 13th March, 2019.

Notes for the Editor

EXCiPACT asbl provides management oversight for the high quality, voluntary, international EXCiPACT Certification Scheme that provides for independent, third-party GMP and/or GDP certification of manufacturers, suppliers and distributors of pharmaceutical excipients worldwide. The Scheme will ensure patient safety through supplier quality while minimising the overall costs for assessing the excipient supply chain. It has been operational since early 2013 since when there has been considerable interest among pharmaceutical excipient suppliers, customers and regulators. For further information see www.excipact.org or contact info@excipact.org

¹ Programme subject to amendment